Bladder to Breast Milk—DMSO Treatment of Interstitial Cystitis

Abstract

Objective:

This study aimed to be the first to quantify dimethyl sulfoxide (DMSO) concentrations in human milk after the maternal dosing and estimate the relative infant dose (RID) to assess potential safety concerns.

Methods:

Human milk samples were obtained at different time points after the mother had received one Rimso-50 treatment. The concentrations of DMSO were then quantified at each time interval by a liquid chromatography-mass spectrometry.

Results:

The maximum concentration (Cmax) was observed to be 34.5 μg/mL at hour 5 post-treatment. The RID was calculated to be 0.45%, while the estimated infant dose was found to be 2 mg/kg/day.

Conclusion:

The findings of the study demonstrate that DMSO’s transfer into human milk is minimal. Additionally, the study provides the first quantification of DMSO in human milk.

Keywords

dimethyl sulfoxide DMSO human milk Rimso-50 relative infant dose

Get full access to this article

View all access options for this article.

References

1. Hanno

, Dmochowski

. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn 2009;28(4):274–286; doi: 10.1002/nau.20687

2. Lukban

, Parkin

, Holzberg

, et al. Interstitial cystitis and pelvic floor dysfunction: A comprehensive review. Pain Med 2001;2(1):60–71; doi: 10.1046/j.1526-4637.2001.002001060.x

3. Berry

, Elliott

, Suttorp

, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol 2011;186(2):540–544; doi: 10.1016/j.juro.2011.03.132 20110616

4. Daniels

, Schulte

, Herndon

. Interstitial cystitis: An update on the disease process and treatment. J Pain Palliat Care Pharmacother 2018;32(1):49–58; doi: 10.1080/15360288.2018.1476433

5. Patnaik

, Lagana

, Vitale

, et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch Gynecol Obstet 2017;295(6):1341–1359; doi: 10.1007/s00404-017-4364-2

6. Clemens

, Erickson

, Lai

. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Reply. J Urol 2022;208(6):1178–1179; doi: 10.1097/JU.0000000000002974

7. Rawls

, Cox

, Rovner

. Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review. Neurourol Urodyn 2017;36(7):1677–1684; doi: 10.1002/nau.23204

8. Hucker

, Miller

, Hochberg

, et al. Studies on the absorption, excretion and metabolism of dimethylsulfoxide (DMSO) in man. J Pharmacol Exp Ther 1967;155(2):309–317.

9. Kollerup Madsen

, Hilscher

, Zetner

, et al. Adverse reactions of dimethyl sulfoxide in humans: A systematic review. F1000Res 2018;7:1746; doi: 10.12688/f1000research.16642.2

10.

10. Swanson

. Medical use of dimethyl sulfoxide (DMSO). Rev Clin Basic Pharm 1985;5(1–2):1–33.

11.

11. Bennett

., ed. Drugs and human lactation: a comprehensive guide to the content and consequences of drugs, micronutrients, radiopharmaceuticals, and environmental and occupational chemicals in human milk. 2nd ed. Amsterdam; New York: Elsevier, 1996, p.ix, 712 p.